Opdivo’s commercial potential will likely take a hit in the wake of new Keytruda data, but the impact may depend on the ability of BMS to market the message that its I-O/I-O combo allows patients to delay chemo.
Dr. Jessica Grossman, Medicines360
May 1, 2018
12:00 pm
Dr. Jessica Grossman is CEO of Medicines360.
Pro ad report 2017: Ad revenue plunged for print-first publishers
April 4, 2018
11:30 am
The 2017 numbers aren’t kind to print-first publishers. Is this a blip in print’s fortunes or the start of a long-predicted decline?
Whatever REDUCE-IT ultimately reveals (results from the completed study are expected in Q2 or Q3 2018), Salyer maintains Amarin has “a great story to tell, with or without the data.”
Armed with predictive analytics, PBMs push adherence as a stand-in for outcomes
Second to market and dismissed as inferior to the competition, Sanofi’s Aubagio seemed destined for lower-tier status. Here’s how it overcame the initial obstacles and, five years later, become a potent market force
Why haven’t biosimilars gained ground in the U.S.?